Edison Investment Research - Wheaton Precious Metals Corp (WPM) Wheaton Precious Metals - Honing Q322 forecasts

Report

Edison Investment Research

Alison Turner

Wheaton Precious Metals - Honing Q322 forecasts

Wheaton’s Q322 results are scheduled for 3 November after the market closes in Toronto. Ahead of their release, we have updated our forecasts to reflect recent moves in precious metals prices, forex, Wheaton’s share price and Vale’s Q322 production report (released on 17 October), which gives an indication of possible gold production at Salobo.

24/10/2022 1 EN

Underlying

Wheaton Precious Metals Corp

Wheaton Precious Metals is engaged in the silver mining business.

See profile

CA9628791027 Toronto Stock Exchange Canada

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Alison Turner

Other Reports on these Companies

SmartInsider

Wheaton Precious Metals Corp: 3 directors

Three Directors at Wheaton Precious Metals Corp sold/sold after exercising options 20,800 shares at between 76.500CAD and 76.636CAD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trad...

Free Trial

May 17, 2024 May 17, 2024 1 EN

Edison Investment Research

Wheaton Precious Metals - A strong start to FY24

Wheaton’s (WPM’s) Q124 results exceeded both our and the market’s forecasts. It produced more (with the single exception of gold, which recorded a small negative variance in production) and sold more at higher prices than our prior expectations for the period. This led to a positive 5.6% (US$15.8m) variance in sales that was minimally counteracted by a US$0.8m negative variance in costs (including G&A costs) to result in a US$15.3m (10.3%) positive variance in pre-tax profits that, to all intents and purposes, fell straight through to the bottom line.

May 13, 2024 May 13, 2024 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Long-Term Breakouts for Emerging & Frontier Markets The bullish outlook we initiated in early November 2023 remains intact. The S&P 500 and Nasdaq 100 (QQQ) still refuse to close below their 20-day MAs/21-day EMAs for more than 2-3 consecutive days -- and even if/when they do, important supports are close by, including at 4983-5050 on the S&P 500 and $425-$433 on QQQ (gap supports from 2/22/24). The Fed's next move is almost guaranteed to be a cut (though when it happens is up for debate). And we also continue to get an ever-increasing number of global indexes and Sectors with long-term break...

EUR 46.18

April 10, 2024 April 10, 2024 1 EN

OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim

OSE Immunotherapeutics has announced a considerable expansion of its partnership with Boehringer Ingelheim (BI), including the start of two new projects. The first project aims to broaden the scope of BI 765063 and BI 770371 (two immuno-oncology anti-SIRPα monoclonal antibodies (mAbs) being evaluated as part of the initial collaboration and licence agreement), by investigating the candidates in cardiovascular-renal-metabolic (CRM) diseases. The second project will be a new preclinical program to develop immune-cell activating treatments based on OSE’s cis-targeting anti-PD1/cytokine platform. ...

1h / 8m 1h / 8m 1 EN

Pedro Fonseca

Pedro Fonseca

Worldwide Healthcare Trust - ‘Innovation, innovation, innovation’ say the managers

Worldwide Healthcare Trust’s (WWH’s) co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, are bullish on the outlook for the healthcare industry. They believe that high levels of innovation will be the most important driver of the sector’s performance, although continued robust levels of product approvals and an acceleration in M&A activity are also important considerations. The managers’ successful long-term strategy of favouring emerging (smaller-cap) biotech companies over large-cap pharma companies provided an earnings headwind between early 2021 and mid-2...

3h / 21m 3h / 21m 1 EN

Martyn King

Martyn King

Regional REIT - Q124 DPS unchanged ahead of refinancing

For Q124, Regional REIT (RGL) has maintained the rate of quarterly DPS at 1.2p. We expect DPS for the year will partly depend on RGL’s chosen re-financing route. Meanwhile, RGL’s asset disposal programme continues to progress. Portfolio EPC ratings have continued to show good improvement and, adjusted for disposals, rent roll and occupancy were robust. We have made no changes to our forecasts.

May 22, 2024 May 22, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Wheaton Precious Metals - Honing Q322 forecasts

Wheaton Precious Metals Corp: 3 directors

Wheaton Precious Metals - A strong start to FY24

Vermilion Compass: Weekly Equity Strategy

OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim

Worldwide Healthcare Trust - ‘Innovation, innovation, innovation’ say the managers

Regional REIT - Q124 DPS unchanged ahead of refinancing

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe